Conducting Clinical Trials Under ICH GCP
September 28-29, 2016
Philadelphia, PA
CRA & CRC: Beginner Program
September 27-29, 2016
San Francisco, CA
Auditing Techniques for Clinical Research Professionals
October 11-12, 2016
San Francisco, CA

FDA's Human Subject Protection (HSP) Bioresearch Monitoring (BIMO) Initiative September 2010

Sep 30, 2010
Order the DVD of this seminar

Course Description 

In response to public concern, and federal inquiry, stemming from myriad current events involving the oversight of the products it regulates, the FDA has recently developed and issued new regulations, guidance, and procedures to support the agency’s mission to improve the conduct of clinical trials, assess the accuracy and reliability of clinical trial data, and secure the protection of human research participants involved in those trials. This course will address some of the incidents that have led to these new developments, the federal agencies involved in overseeing the FDA, their findings, and how the FDA’s response to the recommendations will impact the conduct of clinical trials.



Learning Objectives 

  • Describe causal factors and their relation to the current clinical research environment
  • Examine key areas of concern from Congress, the Office of the Inspector General (OIG), and the General Accounting Office (GAO)
  • Identify new regulations, guidance, procedures, coalitions, and working groups, and pending and proposed legislation

Who Should Attend 

  • Clinical Quality Assurance Professionals
  • Clinical Research Associates
  • Project Managers
  • Clinical Investigators
  • Study Coordinators
  • IRB Professionals
  • Institutional Officials involved in oversight of clinical research
  • GCP -Focused Regulatory Affairs Professionals 


Elizabeth Ronk Nelson, MPH


Click here for complete trainer biographies 

Course Length Time 

2 hours; 1:00 - 3:00 p.m. Eastern

Course Dates 

September 30, 2010

Hold this course at your company!For more information, contact Naila Ganatra at (215) 413-2471